While NRF2 plays a fundamental role in maintaining redox homeostasis and cytoprotection, its persistent activation in malignancies, especially in p53-mutant tumors, drives tumor survival, therapy resistance, and metabolic reprogramming. This evidence concerns the gene NFE2L2 and neoplasm.